Previous 10 | Next 10 |
Don't let DexCom 's (NASDAQ: DXCM) drop of 38% this year fool you: This business is teeming with growth, and it's still fully capable of being a great long-term investment, especially starting this week. The medical device manufacturer will report its second-quarter earnings after t...
Dexcom provides more choice to users by launching Spanish-language capabilities for its mobile app for the best-selling real-time CGM in the world Spanish-speaking patients can opt to use the Dexcom G6 app in their preferred language, eliminating a language barrier for optim...
Medtronic is the world’s largest pure-play medical device company. It is a dividend aristocrat, conservatively financed and well diversified. It seems like a great long-term investment. The company piqued my interest because of its diabetes portfolio, however, I found that mana...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With a rebound likely , investors are looking for biotech stocks to buy on the dip. According to Investor’s Business Daily, there’s been a collective 22.5% surge among the biotech stocks they’re...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
Down 20% from its January high and within reach of new 52-week lows, the S&P 500 (SNPINDEX: ^GSPC) may be ready to recover -- or maybe not. We just don't know. What we do know is a slew of S&P 500 constituents have suffered even bigger setbacks and are primed to bounce b...
Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by Great Place to Work Institute® Canada, the global authority on high-trust, high...
DexCom (NASDAQ: DXCM) and Intuitive Surgical (NASDAQ: ISRG) without question rank as two of the most disruptive companies in healthcare. Both stocks have been big winners, with DexCom delivering the greatest gains in recent years. But which stock is the better pick for the c...
The Strategy underperformed during another difficult quarter for growth stocks, with weakness centered among several COVID-19 beneficiaries that are seeing tough comparisons, rising input costs or both. Positioning moves during the quarter, which included additions in health care and ...
The Strategy underperformed during another difficult quarter for growth stocks, with weakness centered among several COVID-19 beneficiaries that are seeing tough comparisons, rising input costs or both. Positioning moves during the quarter remained focused on promoting stability and i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...